Close Menu

NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services last week released preliminary gapfill rates for 2017 from its Medicare Administrative Contractors (MAC) for a number of molecular diagnostic tests.

CMS' proposed median payment would reduce pricing for CareDx's AlloMap by 74 percent to $732; Veracyte's Afirma GEC by 30 percent to $2,240; and Genomic Health's Oncotype DX Colon by 72 percent to $849. CMS has proposed to essentially maintain pricing for Myriad Genetics' Vectra DA at $587.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.

May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. 

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.